Construction of Recombinant Adenovirus Vaccine against SARS-CoV
Date Issued
2004
Date
2004
Author(s)
Yang, Wen-Chieh
DOI
zh-TW
Abstract
The Severe acute respiratory syndrome (SARS) is a newly emerged disease with high infectivity and morbidity. It caused the global pandemic between February and July in 2003. As of July 31, 2003, SARS has been affecting 8098 individuals and causing 774 deaths (WHO). The causative agent for SARS has been identified as a novel coronavirus, the SARS-CoV. There are no effective therapies for SARS at present and it is very important to prevent the reemergence of SARS. Among the viral vectors used in vaccine design, recombinant adenovirus is known for high-level protein expression and efficient induction of neutralizing antibody and/or cellular immunity in many virus diseases, yet only causes mild illness in humans. Besides, recombinant adenovirus vaccine can induce mucosal immunity, which can effectively protect host from viral diseases disseminated through mucosa. In this study, we used the recombinant adenovirus as vactor and the three SARS structure proteins, spike (S), membrane (M) and envelope (E) as targets, to develop SARS vaccines. We have constructed three recombinant adenoviral vectors encoding S (Adv/S), M and E (Adv/ME) or S, M and E (Adv/SME), respectively. The pShuttle plasmids encoding the M/E and S, were used as DNA vaccines. Three immunization strategies, DNA immunization, ADV vaccination and DNA/ADV prime-boost immunization regimen were performed in mice to compare their efficiency in inducing humoral and cellular immune responses. The SARS-CoV specific antibody induced by the recombinant adenovirus vaccines and DNA vaccine will be determined by ELISA.
Subjects
重組腺病毒載體
DNA疫苗
嚴重急性呼吸道症候群
recombinant adenoviral vectors
SARS-CoV
DNA vaccines
SDGs
Type
other